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Objectives:  To  assess  the diagnostic  value  of multiparametric-MRI  (MPMRI)  with  hypoxia  imaging as
a  functional  marker  for characterizing  and  detecting  vaginal  vault/local  recurrence  following  primary
surgery  for  cervical  cancer.
Methods:  With  institutional  review  board  approval  and  written  informed  consent  30  women  (median
age:  45  years)  from  October  2009  to  March 2010  with  previous  operated  carcinoma  cervix  and  suspected
clinical  vaginal  vault/local  recurrence  were  examined  with  3.0T-MRI.  MRI  imaging  included  conventional
and  MPMRI  sequences  [dynamic  contrast  enhanced  (DCE),  diffusion  weighted  (DW), 1H-MR  spectroscopy
(1HMRS),  blood  oxygen  level  dependent  hypoxia  imaging  (BOLD)].  Two  radiologists,  blinded  to  pathologic
ﬁndings,  independently  assessed  the  pretherapy  MRI ﬁndings  and then  correlated  it with  histopathology
ﬁndings.  Sensitivity,  speciﬁcity,  positive  predictive  value,  negative  predictive  value  and  their  conﬁdence
intervals  were  calculated.  The  pre  and  post  therapy  conventional  and  MPMRI  parameters  were  analyzed
and correlated  with  response  to  therapy.
Results:  Of  the  30 patients,  there  were  24  recurrent  tumors  and  6 benign  lesions.  The  accuracy  of  diag-
nosing  recurrent  vault  lesions  was highest  at  combined  MPMRI  and  conventional  MRI  (100%)  than  at
conventional-MRI  (70%)  or MPMRI  (96.7%)  alone.  Signiﬁcant  correlation  was  seen  between  percentage
tumor  regression  and  pre-treatment  parameters  such  as  negative  enhancement  integral  (NEI)  (p =  0.02),
the  maximum  slope  (p =  0.04),  mADC  value  (p  =  0.001)  and amount  of hypoxic  fraction  on the  pretherapy
MRI  (p =  0.01).
Conclusion:  Conventional-MR  with  MPMRI  signiﬁcantly  increases  the  diagnostic  accuracy  for  suspected
vaginal  vault/local  recurrence.  Post  therapy  serial  MPMRI  with  hypoxia  imaging  follow-up  objectively
documents  the  response.  MPMRI  and  BOLD  hypoxia  imaging  provide  information  regarding  tumor  biol-
ogy at  the  molecular,  subcellular,  cellular  and  tissue  levels  and  this  information  may  be used  as  an
appropriate  and  reliable  biologic  target  for radiation  dose  painting  to optimize  therapy  in  future.
© 2015  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: MPMRI, multiparametric-MRI; DCE, dynamic contrast enhanced;
DWI, diffusion weighted imaging; 1HMRS, proton magnetic resonance spec-
troscopy; BOLD, blood oxygen level dependent; NEI, negative enhancement integral;
ADC, apparent diffusion coefﬁcient; PD-IDEAL, proton density iterative decomposi-
tion of water and fat with echo asymmetric and least-squares estimation.
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E-mail addresses: abhishek.mahajan@kcl.ac.uk, drabhishek.mahajan@yahoo.in
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1. Introduction
Cervical carcinoma is the third most common gynecologic
malignancy. Approximately 85% of the global burden is from devel-
oping countries, where it accounts for 13% of all female cancers [1].
Even though there have been signiﬁcant advances in surgical tech-
niques, radiotherapy, and chemotherapy, still approximately 30% of
patients with invasive cervical carcinoma die as a result of residual
or recurrent disease [2].
Survival has improved with advances in the management of
these patients with additional radiation therapy or chemotherapy,
http://dx.doi.org/10.1016/j.ejro.2015.11.003
2352-0477/© 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Diagnostic ﬂowchart of patient population.
still early detection of recurrent cervical carcinoma is imperative.
The follow-up after primary therapy is usually performed with
clinical examination and imaging {computed tomography (CT) or
magnetic resonance imaging (MRI)}  [3,4]. Because of the wide
availability and certain advantages, such as rapid acquisition time,
lack of bowel motion artifact, and fewer contraindications than
MRI, CT is most widely used for follow up and is a diagnostic tool for
detection of recurrence [3]. However, the value of CT in differentiat-
ing recurrence from postoperative changes/post radiation ﬁbrosis
is limited [3,4]. Fewer studies exist in literature to conﬁrm the use-
fulness of MRI  over CT for diagnosis of recurrent cervical carcinoma
and differentiating it from radiation ﬁbrosis [3,4,5].
Combined anatomic and physiologic information at multi-
parametric MRI  (MPMRI) with BOLD hypoxia imaging makes it
an interesting tool for detection and grading of tumors. MPMRI
has been extensively used in diagnosing and characterizing pro-
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Fig. 2. (a) BOLD post-processing of the lesion which shows a rainbow color spectrum where central red spectra represented the highest R2* levels, indicating the maximum
concentration of deoxyhaemoglobin suggestive of diffusion related chronic hypoxia, with intermediate yellow spectra representing relatively lower R* levels than that of red
corresponding to anemic hypoxic zone and outer most green spectra suggestive of acute perfusion related hypoxia. Blue spectra represented the lowest R2* levels, indicating
the  minimum concentration of deoxyhaemoglobin. (b) Pre and post therapy comparison of the hypoxic fraction in the recurrent tumor is shown with signiﬁcant regression
in  the central chronic diffusion related hypoxic fraction zone and conversion of the tumor biology from chronic to acute perfusion and anemic zone zones having lower levels
of  deoxyhaemoglobin levels, suggestive of response to therapy. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web  version
of  this article.)
Fig. 3. Case 1: Histopathological conﬁrmed vault recurrence. On conventional MRI  showing Iso-hypointense on T2 W image (a) with mild post contrast enhancement on
LAVA  sequence (b). On DWI  there was restricted diffusion (c) with low ADC value (d), on MRS  elevated choline at 3.2 ppm (e) and on DCE-MRI area of Hhyperperfusion was
noted  (f).
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Fig. 4. Case 2: Histopathological conﬁrmed vault recurrence. On conventional MRI  showing Iso-hypointense on T2 W image (a) with heterogeneous post contrast enhancement
on  LAVA sequence (b). On DWI  there was restricted diffusion (c) with low ADC value (d), on BOLD image area of two small hypoxic foci were noted represented by red color,
the  rest of the tissue was  relatively well oxygenated represented by green and blue colors (e) and on MRS  elevated choline at 3.2 ppm (f). (For interpretation of the references
to  colour in this ﬁgure legend, the reader is referred to the web  version of this article.)
static cancer and post radical prostatectomy recurrences. Diffusion
weighted imaging has shown promising results in evaluating
primary cervical cancer as well as postoperative vault/local recur-
rences and is found to be biomarker for predicting response to
therapy in both scenarios. Similarly Dynamic contrast enhanced
(DCE) MR  Imaging and 1H MR  spectroscopy (1H MRS) has also been
investigated as a potential imaging biomarker for both primary and
postoperative recurrent cervical cancers.
Literature on the role of combined use of these functional
biomarker parameters constituting MPMRI  with hypoxia imaging
in diagnosing vaginal vault/local recurrence in postoperative carci-
noma cervix is sparse and discordant and the diagnostic relevance
of MPMRI  and hypoxia imaging is underutilized. So we  aimed to
evaluate the role of MPMRI  with hypoxia imaging as a functional
marker for the detection of vaginal vault/local recurrence following
primary surgery for cervical cancer. The ﬁndings were compared
to the ﬁnal Histopathological diagnosis. The objectives of the study
were:
1. To characterize suspected postoperative vaginal vault/local
recurrent cervical cancer lesions on MPMRI  with BOLD hypoxia
imaging.
2. To assess the diagnostic value of MPMRI  and hypoxia imaging as
functional marker to determine the tumor recurrence in post-
operative cases of cervical cancer.
2. Materials and methods
2.1. Study design and population
The study was approved by institutional review board and
the hospital ethics committee. From Oct 2009 to March 2010, 45
consecutive women with previously operated carcinoma cervix
with suspected vault/local recurrence were recruited in the study.
Patients who  had a ﬁnal histopathology diagnosis and all the
required MPMRI  and hypoxia imaging sequences were included
in the analysis and patients with no previous surgical details,
without histopathological diagnosis and who were lost to fol-
low up were excluded from the ﬁnal analysis. The prospective
radiologic-pathologic database included 30 patients which were
included for the ﬁnal analysis. All patients underwent baseline CT
and MPMRI  and were followed up for two  years. Of the 30 post
operated carcinoma cervix patients with suspected clinical vaginal
vault/local recurrence, 24 had histologically conﬁrmed recurrent
lesions (Fig. 1). The median age at recurrence was  45 years (range
34–72 years).
There were four cases of benign ﬁbrotic lesion with inﬂamma-
tory changes and two  had ﬁbrotic changes with superadded local
infection. The cases with with superadded infection were followed-
up with MPMRI  imaging.
Of the 24 recurrent cases, 16 (67%) had squamous carcinoma,
6 (25%) had adenocarcinoma and 2 (8%) had adenosqaumous
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Fig. 5. (A and B). Case 3: Conventional and MPMRI  in a case of vault recurrence: pre and post therapy imaging ﬁndings. Conventional and MPMRI  comparison showed that
there  was a mild interval regression of tumor volume with no signiﬁcant change in the enhancement (a, b and i, j). On DWI  images there was interval regression on the
restricted component with signiﬁcant increase in the ADC values (c, d and k, l). On DCE-MRI there is a signiﬁcant regression of the perfusion with a signiﬁcant decrease in the
slope  of enhancement (e, f and m,  n). On BOLD sequence there was a small central core of hypoxia which on follow up showed signiﬁcant regression in the chronic hypoxic
fractions and near normal oxygenation (g and o). On MRS  the choline peak noted at 3.2 peak was  absent in the follow up MRS (h and p). All these ﬁndings were suggestive
of  response to therapy, predicted at the molecular level with not much change in the morphology of the lesion.
Table 1
MR imaging parameters for conventional and MPMRI  sequences.
Sequence TE TR Slice thickness Slice gap Field of view Matrix NEX Band width Flip angle Echo train length
AXIAL T1 10 400 3 1 40 320 × 224 4 41.67 – 5
AXIAL  T2 100 5000 3 1 40 320 × 224 4 41.67 – 21
AXIAL  T2CUDE 3D 20 2000 3 1 40 256 × 256 1 41.67 – 40
SAGITTAL T2 100 5000 3 1 24 256 × 256 4 41.67 – 19
CORONAL T2 6 5000 3 1 32 256 × 256 4 31.25 – 19
BOLD#  30 2000 3 1 40 256 × 256 1 – 90 –
DWI  b value 0 and 700 100 6000 3 1 40 256 × 256 8 – – –
PD-IDEAL 30 4000 3 1 40 256 × 265 2 83.33 – 10
DCE  10 1600 3 1 40 256 × 256 1 – 80 –
LAVA  + C@ 2.3 4.7 40 256 × 256 1 62.5 15 –
AXIAL  T1 + C 10 1000 3 1 40 320 × 224 4 41.67 5
CORONAL T1 + C 10 400 3 1 32 256 × 256 4 41.67 80
SAGITAL T1 + C 10 600 3 1 24 256 × 256 4 41.67 5
MRSa 155 2000 32
# T2*-weighted gradient-echo imaging was performed for BOLD imaging on normal breathing.
@: Intravenous injection of Gadobenate dimeglumine (MultiHance; Bracco Imaging) administered at a rate of 2 ml/s and at a dose of 0.1 mmol/kg of body weight followed
by  20 ml  saline ﬂush (0.9%) by using a power injector.
a 1H-MRS breast spectroscopy sequence named MR BREASE which is a point-resolved spin-echo sequence with regional saturation bands for outer volume suppression
was  used for MRS.
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carcinoma. The median time interval from baseline MPMRI  to
the histopathology conﬁrmation was 7.5 days (range 1–12 days).
Of the 24 patients, 12 patients had an additional post-chemo-
radiotherapy MPMRI, the mean interval between the baseline
MPMRI  scan and the 1st port therapy MPMRI  scan was  180 days.
2.2. MR  imaging methodology and data analysis
MPMRI  protocol was  standardized in all cases. MRI  was per-
formed on the 3.0-T system (GE Signa 3.0T HDx, GE Healthcare,
Milwaukee, WI)  using a torso phased-array with the patient in
the supine position. We  used approximately 60 ml  of bacterio-
static ultrasound jelly to distend the vaginal lumen. The various
imaging parameters are summarized in Table 1. After determining
the anatomic orientation of the vault/local was determined on the
localizer images, fast spin-echo T2-weighted images were obtained
in three orthogonal plane. After baseline acquisitions, dynamic
contrast-enhanced (DCE) images were obtained after administra-
tion of a bolus Intravenous injection of Gadobenate dimeglumine
(MultiHance; Bracco Imaging) administered at a rate of 2 ml/s and
at a dose of 0.1 mmol/kg of body weight followed by 20 ml  saline
ﬂush (0.9%) by using a power injector.
For assessment of MPMRI  functional sequences and BOLD
hypoxia imaging, data were transferred to a GE Advantage Work-
station, and manually drawn regions of interest (ROIs) were
analyzed using Advantage Windows, version 4.2.3, GE Healthcare.
The results of MPMRI  were individually analyzed for each func-
tional MRI  sequence.
MR imaging data sets were evaluated by two radiologists with
5 and 14 years of experience in gynecology MR imaging, respec-
tively. MR imaging data sets of T1-weighted and T2-weighted MR
images, PD-IDEAL imaging, three plane post contrast T1-weighted
images, apparent diffusion coefﬁcient (ADC) maps from Diffu-
sion weighted imaging (DWI), MR  spectroscopic images, dynamic
contrast-enhanced MR  images and BOLD (Blood oxygen level
dependent) images were assessed and both reviewers were blinded
to histopathology ﬁndings. The lesion was delineated both the radi-
ologists independently, in the axial T2-weighted images and the
same was transferred from the T2-weighted image series to the
series from the DWI  and DCE-MRI for coordinated mapping of the
disease.
Based on the MR  signal intensity pattern the lesions were cate-
gorized, into three categories:
1. Normal (no focal soft-tissue nodule);
2. Indeterminate (soft-tissue nodule hypointense or isointense to
muscle on T1-weighted sequences and mildly hyperintense to
muscle on T2-weighted sequences);
3. Recurrent (soft-tissue nodule hypointense on T1-weighted
sequence and markedly hyperintense or heterogeneous on T2-
weighted sequences).
For Proton Density Iterative decomposition of water and fat
with echo asymmetry and least-squares estimation (PD-IDEAL)
sequences four set of processed images were obtained and these
were WATER only, FAT only, IN phase and OUT of phase images.
DWI  analysis was done by quantitative analysis of the data
acquired from DWI  and pixel-by-pixel ADC maps were derived
using advantage Windows, version 4.2.3, GE Healthcare. DWI
Images were identiﬁed and matched to enable measurements at
the same anatomic levels and the lesions were localized on the
b = 0 s/mm2 (i.e. b0) images. Obvious areas of air or ﬂuid from central
ulceration were excluded and the ﬁndings on both the eADC and
mADC maps were analysed both qualitatively and quantitatively
(Table 2). Region of interest (ROI) were drawn manually avoiding
negative pixels and subsequent measurements on the anatomi-
cally corresponding ADC maps were generated on a pixel-by-pixel
basis using b values of 0 and 700 s/mm2(ADCb0 − 1000) on dedicated
workstation using the proprietary, manufacturer provided soft-
ware (ADW 4.4). Of the various ROI placed in the lesion, the lowest
ADC value obtained was recorded.
The DCE-MRI series were analyzed on a voxel-by-voxel basis
by using the arterial input function and presented as histograms
for each time point in the dynamic series. Necrosis within the
tumor volume, if present, was included in the delineation. The
ﬁrst-pass DCE method was used to obtain a time-signal intensity
(SI) DCE curve. The perfusion parameter calculated was the neg-
ative enhancement integral (Area under the curve: relative blood
volume).
We used BREASE GE software to obtain robust Choline signals
for MR-spectroscopy analysis. A cubed volume voxel was placed
in the region of interest of critical importance. Total choline con-
taining resonance (tCho) at 3.2 ppm in spectra was qualitatively
determined.
Post processed BOLD maps were generated and ROIs were
marked in the region of interest using an ROI tool to calculate R2*
levels (Fig. 2). Pre and post therapy hypoxic fraction was compared
in all the 24 recurrences treated that were treated with radiother-
apy.
2.3. Treatment and follow-up assessment of response
Patients with histopathological diagnosis of recurrence received
image guided intensity modulated radiotherapy (IG-IMRT) with
concomitant chemotherapy. IG-IMRT schedule consisted of
50 Gy/25 fractions delivered over 5 weeks along with con-
current weekly cisplatin (40 mg/m2). Response assessment and
brachytherapy preplanning MPMRI  were performed within a week
of completing IG-IMRT. Subsequently, all patients underwent tem-
plate guided high dose pelvic interstitial brachytherapy (20 Gy/5
#/3 days).
All cases underwent clinical examination and MPMRI  with BOLD
imaging on ﬁrst follow up at 3 months. All post therapy MRI  scans
were reviewed by two  radiologists. Absence of disease on MRI  was
categorized as “complete response” and the presence of residual
disease as “partial response.” Second MPMRI  with BOLD imaging
was performed at 6 months. Further MRI  imaging was performed
only on clinical suspicion of residual or recurrent disease.
The radiologist was  blinded to the clinical response and the
radiation oncologist was blinded to the MPMRI with BOLD imag-
ing ﬁndings. Conventional MRI  was used by clinicians to evaluate
response to therapy and plan further management. Response on
conventional MRI  was  determined using T2-weighted images in
sagittal and axial planes and calculating the residual tumor size.
Pre and post therapy MPMRI  and BOLD imaging ﬁndings were cor-
related and the changes in the parameter were analyzed to assess
the response.
2.4. Statistical analysis
Statistical analysis was  done to assess correlation between
imaging parameters and pathologic diagnosis. All the relevant data
were entered into SPSS version 16.0 data sheet for statistical com-
putation. Agreement between the two  radiologists was estimated
by calculating  and was  interpreted as follows: 0.00–0.20, poor
agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agree-
ment; 0.61–0.80, substantial agreement; and 0.81–1.00, almost
perfect agreement [6]. The sensitivity, speciﬁcity, accuracy, pos-
itive predictive value and negative predictive value of MPMRI,
were calculated using standard 2 × 2 tables, by comparing with
the gold standard of ﬁnal histopathology. Measures of diagnostic
performance were estimated based on individual and combined
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Table  2
Diffusion characteristics of the lesions.
Signal intensity on T2-weighted images Signal intensity on exponential maps Values on ADC maps Interpretation of ﬁndings
Isointensity, hyperintensity Hyperintensity Decreased High-cellularity recurrent tumour
Hypointensity, isointensity Hypointensity Decreased Fibrous tissue/scar tissue
Hyperintensity Hypointensity Increased Benign normal
mucosa/inﬂammation/post
therapy necrosis
Table 3
Diagnostic performance of conventional and MPMRI  sequences in detecting recurrent lesions.
Conventional MRI  MPMRI  Combined MRI  DCE DWI  MRS  PD-IDEAL BOLD
Sensitivity (%) (CI) 70.8 (48.7–86.5) 95.8 (76.8–99.7) 100 (82.8–100) 91.6 (71.5–98.5) 95.8 (76.8–99.7) 81.8 (58.9–94.0) 95.8 (76.8–99.7) 91.6 (71.5–98.5)
Speciﬁcity (%) (CI) 66.6 (24.1–94.0) 100 (51.6–100) 100 (51.6–100) 100 (51.6–100) 100 (51.6–100) 100 (19.7–100) 83.3 (36.4–99.1) 100 (51.6–100)
PPV  (%) (CI) 89.4 (65.4–98.1) 100 (82.1–100) 100 (82.8–100) 100 (81.5–100) 100 (82.1–100) 100 (78.1–100) 95.8 (76.8–99.7) 100 (81.5–100)
NPV  (%) (CI) 36.4 (12.3–68.3) 85.7 (42.0–99.2) 100 (51.6–100) 75.0 (35.5–95.5) 85.7 (42.0–99.2) 33.3 (6.0–75.8) 83.3 (36.4–99.1) 75.0 (35.5–95.5)
Accuracy 70 96.7 100 93.3 96.7 73.3 93.3 93.3
probability for correctly identifying the recurrence. Results were
expressed as point estimates and their 95% CIs were derived from
the binomial distribution. All p-values were two-tailed. P-value
below 0.05 was considered signiﬁcant. Statistical signiﬁcance was
also considered demonstrated if the 95% conﬁdence intervals did
not include zero.
3. Results
The mean diameter of soft-tissue nodules revealed at MRI  was
1.5 cm (range, 0.7–4.8 cm). Based on the conventional imaging ﬁnd-
ings the lesions were categorized as: 11 in category 1 and 19 in
category 2 and 3. The conventional and MPMRI  appearances of
lesions were analyzed and compared qualitatively. Statistical val-
ues of the conventional and MPMRI  imaging tests are summarized
in Table 3.
Combined qualitative and quantitative analysis of conventional
MRI  and MPMRI  of the 11 patients in category 1, based on con-
ventional sequences only, four were true negative and seven were
false negative. These cases however were picked up as recurrence
on MPMRI  and showed restricted diffusion on DWI  and hyper-
perfusion on quantitative color maps of DCE-MRI, suggestive of
recurrence.
Similar analysis of 19 patients in category 2 and 3, based on
conventional sequences only, two were false positive. These two
cases showed T2 hyperintensity on conventional imaging with
post-contrast enhancement however on MPMRI  they had facili-
tated diffusion with hypoperfusion and no elevated choline peak.
The  statistics agreement between the two radiologists for con-
ventional MRI  reading, MP-MRI reading and Combined MP-MRI
images were 0.70, 0.65, and 0.69 respectively and the interobserver
agreement was substantial.
3.1. MPMRI  parameters
Statistical analyses of various MPMRI  sequences are summa-
rized in Table 3.
The DWI  ﬁndings were compared to the T2W signal intensity of
the lesion and are summarized in Table 2. A statistically signiﬁcant
difference in the ADC values was observed between the benign tis-
sue and recurrent lesions (p < 0.001). Restricted diffusion was  seen
in 23 of the 24 cases and all the benign cases showed facilitated
diffusion. We found that the median ADC (mADC) of recurrent car-
cinomas (1.23 ± 0.20 × 10−3 mm2/s) was signiﬁcantly lower than
benign vault tissue (2.56 ± 0.46 × 10−3 mm2/s) (p < 0.001).
Based on DCE- MRI, 22 cases showed ﬁndings suggestive of
recurrence with no false positive cases and 8 cases showed hypop-
erfusion with 2 false negative cases. The recurrent lesions showed
evidence of hyperperfusion with NEI of 354%. This was  statisti-
cally higher than the values seen in benign cases (NEI of 76%, p
value < 0.05).
1H-MRS was  performed in 24 patients of which, 18 were positive
for recurrence and showed signiﬁcantly elevated choline. Two  cases
were benign and showed no elevated choline. There were four false
negative cases. Spectroscopy could be performed in 6 cases because
of the lesion was  too small and had admixture of normal tissue in
the spectroscopy voxel.
Based on the ﬁndings on PD-IDEAL imaging, suspicion of recur-
rence was  raised in 24 cases and only one false positive case
was documented.These lesions showed signiﬁcant hyperintensity
on WATER images and were hypointense on FAT images. 6 cases
were diagnosed as benign on PD-IDEAL imaging which showed
hypointensity on WATER images. There was  one false negative case.
Qualitative and quantitative estimation of hypoxic fraction was
performed using BOLD MRI. Of the 24 cases 22 had hypoxia on
pretherapy MRI. Compared to benign ﬁbrosis the recurrent lesions
showed predominantly red maps representing higher R2* levels
suggestive of higher concentration of deoxyhaemoglobin with a
higher oxygen metabolism and very low tumor perfusion sugges-
tive of chronic hypoxia (Figs. 3 and 4).
3.2. Follow up imaging to assess treatment response
Follow up imaging was  performed in all the 24 recurrent cases
to assess the therapy response. Of the 6 benign cases, 2 had one
follow up MRI  to check for local infection and showed no evidence
of any disease after effective antibiotic therapy.
21 out of the 24 Post therapy follow-up MPMRI  revealed sig-
niﬁcant increase in mADC values, with regression in the perfusion
parameters of the lesion in 19 of the 22 cases and regression in
the choline peak in 15 of the 19 cases. In 14 cases, correlation
of combined all three parameters showed statistically signiﬁcant
correlation with response to therapy. We  found a signiﬁcant cor-
relation between percentage tumor regression and pre-treatment
parameters: NEI (p = 0.02), the maximum slope (p = 0.04) and mADC
value (p = 0.001).
Of the 22 cases that showed signiﬁcant intratumoral hypoxic
fraction on BOLD imaging, 18 cases showed statistically inter-
val regression in the hypoxic fractions and signiﬁcant correlation
between the tumor size reduction and the amount of hypoxia
present in the pretherapy MRI  (p = 0.01) Fig. 5.
Three lesions were found to be non-responsive to therapy on
both multiparametric and BOLD MR  imaging. One case showed sig-
niﬁcant increase in the mADC values on post therapy follow-up
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however no signiﬁcant change in the hypoxic fraction was  noted in
this case. In all the nonresponsive cases Pre-therapy BOLD imaging
revealed a signiﬁcantly large chronic hypoxic fraction which did
not change statistically on post-therapy imaging. Overall the post
therapy follow up MPMRI  with BOLD hypoxia imaging parameters
showed statistically signiﬁcant correlation between the changes
in tumor biology at at the molecular, subcellular, cellular and tis-
sue levels (unavailable from routine structural imaging techniques
alone) and response to therapy.
4. Discussion
Post-hysterectomy recurrence in patients with carcinoma
cervix may  involve the vaginal vault, parametrial tissue, urinary
bladder and rectum. The occurrence of these recurrent lesions
varies with the preoperative stage; histology of primary, extent of
surgery and host response [7–10]. Most of these recurrences are
asymptomatic however few patients may  present with symptoms
such as pain due to nerve compression, ureteric involvement or
limb swelling due to lymphatic inﬁltration. Recurrence can be eas-
ily detected on routine clinical examination, surveillance CT, or MR
imaging [7–10].
MRI  is the standard imaging technique indicated for the initial
evaluation of local spread (tumor size, spread to parametria, vagina,
bladder, and rectum) and lymph node status in patients with cer-
vical cancer [11,12,13]. One of the initial studies was  by Hatano
et al. and they reported a correlation between MRI  and cytology
and/or punch biopsy. The reported sensitivity, speciﬁcity, and neg-
ative and positive predictive values of MRI  in their study was 100%,
78%, 43%, and 100%, respectively [12]. Another similar study by Nam
et al., evaluated 38 patients treated with CRT and response evalua-
tion done by MRI. They found 92% radiological response with local
control rate of 100% in these patients [13].
Studies have shown that, similar to other tumors, carcinoma of
the uterine cervix is associated with tumoral angiogenesis leading
to abnormal contrast enhancement patterns [14,15]. Hawighorst
et al. evaluated 24 patients with suspected cervical cancer recur-
rence using pharmacokinetic analysis of dynamic MR  images. They
found that the pharmacokinetic mapping of malignant lesions had
a statistically signiﬁcant shorter (p < 0.005) and stronger (p < 0.001)
contrast medium enhancement (t21, 24 s; A, 1.5 arbitrary units)
than that of benign lesions (t21, 65 s; A, 0.7). The test showed a
sensitivity of 100%, a speciﬁcity of 88%, and an accuracy of 96%
[15]. Similar results have been reported in Yamashita et al. study,
performed to predict response to therapy based on DCE-MRI in
patients with known cervical carcinoma [16]. The rate as well as
the slope of enhancement has also been shown to correlate with
local tumor control and outcome [17]. In our study, these differ-
ences were quantiﬁed and used to discriminate vaginal vault/local
recurrence from postsurgical or residual ﬁbrosis. We  also found
that post-therapy DCE-MRI has a role in predicting recurrence and
identifying those who may  beneﬁt from salvage treatment.
DW imaging with ADC maps have been used to differentiate
between benign and malignant cervical tissues and also to pre-
dict response to chemoradiotherapy on the basis of changes in the
DW parameters in responders and non-responders [18]. Naganawa
et al. showed statistically signiﬁcant difference between the ADC
values of benign and malignant cervical tissues. They reported
mADC of cervical cancer tissue to be 1.09 ± 0.20 × 10−3 mm2/s
while in normal cervix it wasfound to be 1.79 ± 0.24 × 10−3 mm2/s
(p < 0.0001) [19]. The mADC of cervical cancer was  also shown to
have signiﬁcantly increased following chemoradiotherapy and the
rapid increase in ADC values was shown to correlate with tumoral
tissueapoptosis [20,21]. In our study DWI  was found to be not only
helpful in diagnosing recurrent disease but also has potential to
predict response to therapy.
Studies have reported an important limitation of 1HMRS
imaging in cervical cancer patients. There is signiﬁcant spec-
tral contamination on MR  spectra on evaluation of small tumors
which are less than 8 mm leading to inconclusive results [22,23].
Recent studies have shown that 1H-MRS can distinguish pre-
invasive cervical cancers from early invasive lesions. It has also been
shown to help in predicting response to radiotherapy/neoadjuvant
chemotherapy and survival outcome [24,25]. To the best of our
knowledge there is no literature available on the diagnostic value of
MR spectroscopy for detection of vault/local recurrence after rad-
ical hysterectomy. In our series we could perform 1H-MRS in 80%
of patients with sensitivity of 81.8% and speciﬁcity of 100%.
BOLD hypoxia imaging is a promising tool to analyze vascular
functionality associated with angiogenesis [26]. It uses deoxy-
haemoglobin as an intrinsic paramagnetic contrast agent and is
found to be sensitive to changes in blood volume, blood ﬂow and
blood oxygenation [27,28]. Preliminary results of Kim et al. study
suggested that BOLD imaging at 3-T MRI  is an important imag-
ing biomarker and in future it may  have the potential to response
assessment in cervical cancer patients [29,30]. In our study we
found that the tumor maps of BOLD shows three zone of hypoxia
spectra with central core representing chronic hypoxia [30]. This
zone showed signiﬁcant correlation with response assessment on
follow up BOLD imaging. We  found that estimating the central core
volume could be a prognostic marker for predicting response to
therapy.
To conclude, there are existing studies assessing the role of indi-
vidual MPMRI  parameter in evaluating tumoral microenvironment
but to our knowledge, the current study is the ﬁrst to correlate
all the MPMRI  with BOLD hypoxia imaging parameters with his-
tology for recurrent cervical cancer. Furthermore, all patients had
received the same treatment modalities and had a histopathologi-
cal diagnosis which was the gold standard. However, larger studies
are warranted to further establish the role of MPMRI  and BOLD
hypoxia imaging in evaluation of the post-operative recurrent cer-
vical cancers.
5. Conclusion
In our experience, conventional MR  with MPMRI  imaging
signiﬁcantly increases the diagnostic accuracy for suspected vagi-
nal vault/local recurrence with nearly 100% correlation with
histopathological ﬁndings. Therefore, dedicated MPMRI  should
be applied when there is clinical suspicion of recurrence. Post
therapy serial MPMRI  with BOLD hypoxia imaging follow-up objec-
tively documents the response. MPMRI  and BOLD hypoxia imaging
provide information regarding tumor biology at the molecular, sub-
cellular, cellular and tissue levels and this information may  be used
as an appropriate and reliable biologic target for radiation dose
painting to optimize therapy in future.
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